Acasti Pharma Inc V.ACST

Primary Symbol: ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc

<< Previous

Bullboard Posts

Next >>

Post by 19LDS84on Sep 05, 2021 4:21pm

242 Views

Post# 33815818

Nice to see the reverse split went well

Not we can lose more money on this lower board of directors. Why not just admit you suck and go get a real job and stop taking peoples money to dump. Clearly they don't have a clue what they're doing, yet they'll keep taking people down with them. SMH

<< Previous

Bullboard Posts

Next >>

This company starts production at what could be Canada’s next great gold mine